{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:29:23Z","timestamp":1793928563003,"version":"4.8.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T00:00:00Z","timestamp":1553472000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00134-019-05599-w","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T11:02:50Z","timestamp":1553511770000},"page":"789-805","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":212,"title":["ESICM\/ESCMID task force on practical management of invasive candidiasis in critically ill patients"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5834-4063","authenticated-orcid":false,"given":"Ignacio","family":"Martin-Loeches","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Cuenca-Estrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Einav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"De Waele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Garnacho-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souha S.","family":"Kanj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia R.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Montravers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Sakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Sanguinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Timsit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,25]]},"reference":[{"key":"5599_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhin.2017.11.020","volume":"1","author":"R-A O\u2019Leary","year":"2018","unstructured":"O\u2019Leary R-A, Einav S, Leone M et al (2018) Management of invasive candidiasis and candidaemia in critically ill adults: expert opinion of the European Society of Anaesthesia Intensive Care Scientific Subcommittee. J Hosp Infect 1:1. \n                    https:\/\/doi.org\/10.1016\/j.jhin.2017.11.020","journal-title":"J Hosp Infect"},{"key":"5599_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jinf.2017.03.011","volume":"75","author":"O Baldesi","year":"2017","unstructured":"Baldesi O, Bailly S, Ruckly S et al (2017) ICU-acquired candidaemia in France: epidemiology and temporal trends, 2004-2013\u2014a study from the REA-RAISIN network. J Infect 75:59\u201367. \n                    https:\/\/doi.org\/10.1016\/j.jinf.2017.03.011","journal-title":"J Infect"},{"key":"5599_CR3","doi-asserted-by":"publisher","first-page":"e101510","DOI":"10.1371\/journal.pone.0101510","volume":"9","author":"MA Pfaller","year":"2014","unstructured":"Pfaller MA, Andes DR, Diekema DJ et al (2014) Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004\u20132008. PLoS One 9:e101510. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0101510","journal-title":"PLoS One"},{"key":"5599_CR4","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00134-014-3400-y","volume":"40","author":"AL Colombo","year":"2014","unstructured":"Colombo AL, Guimar\u00e3es T, Sukienik T et al (2014) Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med 40:1489\u20131498. \n                    https:\/\/doi.org\/10.1007\/s00134-014-3400-y","journal-title":"Intensive Care Med"},{"key":"5599_CR5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR et al (2016) Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis 62:e1\u2013e50. \n                    https:\/\/doi.org\/10.1093\/cid\/civ933","journal-title":"Clin Infect Dis"},{"key":"5599_CR6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/MCC.0000000000000124","volume":"20","author":"I Martin-Loeches","year":"2014","unstructured":"Martin-Loeches I, Diaz E, Valles J et al (2014) Risks for multidrug-resistant pathogens in the ICU. Curr Opin Crit Care 20:516\u2013524. \n                    https:\/\/doi.org\/10.1097\/MCC.0000000000000124","journal-title":"Curr Opin Crit Care"},{"key":"5599_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4161\/viru.26187","volume":"5","author":"J Delaloye","year":"2014","unstructured":"Delaloye J, Calandra T (2014) Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence 5:161\u2013169. \n                    https:\/\/doi.org\/10.4161\/viru.26187","journal-title":"Virulence"},{"key":"5599_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13054-016-1313-6","volume":"20","author":"T Calandra","year":"2016","unstructured":"Calandra T, Roberts JA, Antonelli M et al (2016) Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy. Crit Care 20:125. \n                    https:\/\/doi.org\/10.1186\/s13054-016-1313-6","journal-title":"Crit Care"},{"key":"5599_CR9","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1007\/s00134-016-4560-8","volume":"42","author":"J-LJ-L Vincent","year":"2016","unstructured":"Vincent J-LJ-L, Martin-Loeches I, Annane D (2016) What patient data should be collected in this randomized controlled trial in sepsis? Intensive Care Med 42:2011\u20132013. \n                    https:\/\/doi.org\/10.1007\/s00134-016-4560-8","journal-title":"Intensive Care Med"},{"key":"5599_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1086\/504810","volume":"43","author":"KW Garey","year":"2006","unstructured":"Garey KW, Rege M, Pai MP et al (2006) Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43:25\u201331. \n                    https:\/\/doi.org\/10.1086\/504810","journal-title":"Clin Infect Dis"},{"key":"5599_CR11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00134-014-3310-z","volume":"40","author":"M Bassetti","year":"2014","unstructured":"Bassetti M, Ansaldi F, Diaz-Martin A et al (2014) A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med 40:839\u2013845. \n                    https:\/\/doi.org\/10.1007\/s00134-014-3310-z","journal-title":"Intensive Care Med"},{"key":"5599_CR12","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00134-017-4990-y","volume":"43","author":"J-A Paiva","year":"2017","unstructured":"Paiva J-A, Charles P-E (2017) Biomarker-guided antifungal therapy in patients with suspected invasive candidiasis: ready for prime time? Intensive Care Med 43:1889\u20131891. \n                    https:\/\/doi.org\/10.1007\/s00134-017-4990-y","journal-title":"Intensive Care Med"},{"issue":"Suppl 7","key":"5599_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12039","volume":"18","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Bassetti M, Calandra T et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):19\u201337. \n                    https:\/\/doi.org\/10.1111\/1469-0691.12039","journal-title":"Clin Microbiol Infect"},{"key":"5599_CR14","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1586\/14787210.2015.1029916","volume":"13","author":"E Tagliaferri","year":"2015","unstructured":"Tagliaferri E, Menichetti F (2015) Treatment of invasive candidiasis: between guidelines and daily clinical practice. Expert Rev Anti Infect Ther 13:685\u2013689. \n                    https:\/\/doi.org\/10.1586\/14787210.2015.1029916","journal-title":"Expert Rev Anti Infect Ther"},{"key":"5599_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1055\/s-0031-1275528","volume":"32","author":"PM Echeverria","year":"2011","unstructured":"Echeverria PM, Kett DH, Azoulay E (2011) Candida prophylaxis and therapy in the ICU. Semin Respir Crit Care Med 32:159\u2013173. \n                    https:\/\/doi.org\/10.1055\/s-0031-1275528","journal-title":"Semin Respir Crit Care Med"},{"key":"5599_CR16","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1007\/s00134-013-3109-3","volume":"39","author":"M Bassetti","year":"2013","unstructured":"Bassetti M, Marchetti M, Chakrabarti A et al (2013) A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med 39:2092\u20132106. \n                    https:\/\/doi.org\/10.1007\/s00134-013-3109-3","journal-title":"Intensive Care Med"},{"key":"5599_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1378\/chest.129.1.174","volume":"129","author":"G Guyatt","year":"2006","unstructured":"Guyatt G, Gutterman D, Baumann MH et al (2006) Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American college of chest physicians task force. Chest 129:174\u2013181. \n                    https:\/\/doi.org\/10.1378\/chest.129.1.174","journal-title":"Chest"},{"key":"5599_CR18","unstructured":"Helmer O (1967) Analysis of the future. The RAND corporation, Santa Monica, California. \n                    https:\/\/www.rand.org\/pubs\/papers\/P3558.html\n                    \n                  . Accessed 26 Nov 2018."},{"key":"5599_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1748-5908-6-62","volume":"6","author":"J Hsu","year":"2011","unstructured":"Hsu J, Bro\u017cek JL, Terracciano L et al (2011) Application of GRADE: making evidence-based recommendations about diagnostic tests in clinical practice guidelines. Implement Sci 6:62. \n                    https:\/\/doi.org\/10.1186\/1748-5908-6-62","journal-title":"Implement Sci"},{"key":"5599_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jclinepi.2016.01.032","volume":"76","author":"HJ Sch\u00fcnemann","year":"2016","unstructured":"Sch\u00fcnemann HJ, Mustafa R, Brozek J et al (2016) GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. J Clin Epidemiol 76:89\u201398. \n                    https:\/\/doi.org\/10.1016\/j.jclinepi.2016.01.032","journal-title":"J Clin Epidemiol"},{"issue":"Suppl 7","key":"5599_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1469-0691.12037","volume":"18","author":"AJ Ullmann","year":"2012","unstructured":"Ullmann AJ, Cornely OA, Donnelly JP et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin Microbiol Infect 18(Suppl 7):1\u20138. \n                    https:\/\/doi.org\/10.1111\/1469-0691.12037","journal-title":"Clin Microbiol Infect"},{"key":"5599_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00268-005-7807-z","volume":"30","author":"Y-S Shan","year":"2006","unstructured":"Shan Y-S, Sy ED, Wang S-T et al (2006) Early presumptive therapy with fluconazole for occult Candida infection after gastrointestinal surgery. World J Surg 30:119\u2013126. \n                    https:\/\/doi.org\/10.1007\/s00268-005-7807-z","journal-title":"World J Surg"},{"key":"5599_CR23","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s00134-014-3281-0","volume":"40","author":"C Le\u00f3n","year":"2014","unstructured":"Le\u00f3n C, Ostrosky-Zeichner L, Schuster M (2014) What\u2019s new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. Intensive Care Med 40:808\u2013819. \n                    https:\/\/doi.org\/10.1007\/s00134-014-3281-0","journal-title":"Intensive Care Med"},{"key":"5599_CR24","doi-asserted-by":"publisher","first-page":"733.e1","DOI":"10.1016\/j.cmi.2016.05.008","volume":"22","author":"LE Lopez-Cortes","year":"2016","unstructured":"Lopez-Cortes LE, Almirante B, Cuenca-Estrella M et al (2016) Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort. Clin Microbiol Infect 22:733.e1\u2013733.e8. \n                    https:\/\/doi.org\/10.1016\/j.cmi.2016.05.008","journal-title":"Clin Microbiol Infect"},{"key":"5599_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.medin.2016.03.008","author":"A Rodriguez","year":"2016","unstructured":"Rodriguez A, Martin-Loeches I, Yebenes JC (2016) New definition of sepsis and septic shock: what does it give us? Med Intensiva. \n                    https:\/\/doi.org\/10.1016\/j.medin.2016.03.008","journal-title":"Med Intensiva"},{"key":"5599_CR26","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1097\/00000658-199412000-00008","volume":"220","author":"D Pittet","year":"1994","unstructured":"Pittet D, Monod M, Suter PM et al (1994) Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220:751\u2013758","journal-title":"Ann Surg"},{"key":"5599_CR27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10096-007-0270-z","volume":"26","author":"L Ostrosky-Zeichner","year":"2007","unstructured":"Ostrosky-Zeichner L, Sable C, Sobel J et al (2007) Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 26:271\u2013276. \n                    https:\/\/doi.org\/10.1007\/s10096-007-0270-z","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5599_CR28","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1097\/01.CCM.0000202208.37364.7D","volume":"34","author":"C Leon","year":"2006","unstructured":"Leon C, Ruiz-Santana S, Saavedra P et al (2006) A bedside scoring system (\u201cCandida score\u201d) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 34:730\u2013737. \n                    https:\/\/doi.org\/10.1097\/01.CCM.0000202208.37364.7D","journal-title":"Crit Care Med"},{"key":"5599_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/13693780410001731619","volume":"43","author":"NI Paphitou","year":"2005","unstructured":"Paphitou NI, Ostrosky-Zeichner L, Rex JH (2005) Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 43:235\u2013243","journal-title":"Med Mycol"},{"key":"5599_CR30","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/01.CCM.0000053525.49267.77","volume":"31","author":"H Dupont","year":"2003","unstructured":"Dupont H, Bourichon A, Paugam-Burtz C et al (2003) Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 31:752\u2013757. \n                    https:\/\/doi.org\/10.1097\/01.CCM.0000053525.49267.77","journal-title":"Crit Care Med"},{"key":"5599_CR31","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1378\/chest.124.6.2244","volume":"124","author":"AS Michalopoulos","year":"2003","unstructured":"Michalopoulos AS, Geroulanos S, Mentzelopoulos SD (2003) Determinants of candidemia and candidemia-related death in cardiothoracic ICU patients. Chest 124:2244\u20132255","journal-title":"Chest"},{"key":"5599_CR32","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.jcrc.2015.03.010","volume":"30","author":"CV Guillamet","year":"2015","unstructured":"Guillamet CV, Vazquez R, Micek ST et al (2015) Development and validation of a clinical prediction rule for candidemia in hospitalized patients with severe sepsis and septic shock. J Crit Care 30:715\u2013720. \n                    https:\/\/doi.org\/10.1016\/j.jcrc.2015.03.010","journal-title":"J Crit Care"},{"key":"5599_CR33","doi-asserted-by":"publisher","first-page":"R198","DOI":"10.1186\/cc10366","volume":"15","author":"ED Hermsen","year":"2011","unstructured":"Hermsen ED, Zapapas MK, Maiefski M et al (2011) Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case-control study. Crit Care 15:R198. \n                    https:\/\/doi.org\/10.1186\/cc10366","journal-title":"Crit Care"},{"key":"5599_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/2110-5820-1-50","volume":"1","author":"G Leroy","year":"2011","unstructured":"Leroy G, Lambiotte F, Th\u00e9venin D et al (2011) Evaluation of \u201cCandida score\u201d in critically ill patients: a prospective, multicenter, observational, cohort study. Ann Intensive Care 1:50. \n                    https:\/\/doi.org\/10.1186\/2110-5820-1-50","journal-title":"Ann Intensive Care"},{"key":"5599_CR35","doi-asserted-by":"publisher","first-page":"117.e1","DOI":"10.1016\/j.cmi.2016.10.001","volume":"23","author":"P Montravers","year":"2017","unstructured":"Montravers P, Perrigault PF, Timsit JF et al (2017) Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand2, a prospective cohort study in French intensive care units. Clin Microbiol Infect 23:117.e1\u2013117.e8. \n                    https:\/\/doi.org\/10.1016\/j.cmi.2016.10.001","journal-title":"Clin Microbiol Infect"},{"key":"5599_CR36","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1093\/cid\/cit006","volume":"56","author":"CJ Clancy","year":"2013","unstructured":"Clancy CJ, Nguyen MH (2013) Finding the \u201cmissing 50%\u201d of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 56:1284\u20131292. \n                    https:\/\/doi.org\/10.1093\/cid\/cit006","journal-title":"Clin Infect Dis"},{"key":"5599_CR37","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00134-017-4787-z","volume":"43","author":"I Martin-Loeches","year":"2017","unstructured":"Martin-Loeches I, Garnacho-Montero J, Nseir S (2017) Focus on infection and sepsis 2017. Intensive Care Med 43:867\u2013869. \n                    https:\/\/doi.org\/10.1007\/s00134-017-4787-z","journal-title":"Intensive Care Med"},{"key":"5599_CR38","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00134-016-4234-6","volume":"42","author":"I Martin-Loeches","year":"2016","unstructured":"Martin-Loeches I, Perner A, Loeches IM, Perner A (2016) Focus on infection and sepsis in intensive care patients. Intensive Care Med 42:491\u2013493. \n                    https:\/\/doi.org\/10.1007\/s00134-016-4234-6","journal-title":"Intensive Care Med"},{"key":"5599_CR39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1043\/1543-2165-133.1.93","volume":"133","author":"JE Kirby","year":"2009","unstructured":"Kirby JE, Delaney M, Qian Q, Gold HS (2009) Optimal use of Myco\/F lytic and standard BACTEC blood culture bottles for detection of yeast and mycobacteria. Arch Pathol Lab Med 133:93\u201396. \n                    https:\/\/doi.org\/10.1043\/1543-2165-133.1.93","journal-title":"Arch Pathol Lab Med"},{"key":"5599_CR40","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/jcla.21535","volume":"26","author":"DW Jekarl","year":"2012","unstructured":"Jekarl DW, Lee S-Y, Lee S et al (2012) Comparison of the Bactec Fx Plus, Mycosis IC\/F, Mycosis\/F Lytic blood culture media and the BacT\/Alert 3D FA media for detection of Candida species in seeded blood culture specimens containing therapeutic peak levels of fluconazole. J Clin Lab Anal 26:412\u2013419. \n                    https:\/\/doi.org\/10.1002\/jcla.21535","journal-title":"J Clin Lab Anal"},{"key":"5599_CR41","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1128\/JCM.02048-13","volume":"51","author":"R K\u00f6ck","year":"2013","unstructured":"K\u00f6ck R, Ei\u03b2ing LC, Boschin MG et al (2013) Evaluation of bactec mycosis IC\/F and plus aerobic\/F blood culture bottles for detection of Candida in the presence of antifungal agents. J Clin Microbiol 51:3683\u20133687. \n                    https:\/\/doi.org\/10.1128\/JCM.02048-13","journal-title":"J Clin Microbiol"},{"key":"5599_CR42","doi-asserted-by":"publisher","first-page":"e114834","DOI":"10.1371\/journal.pone.0114834","volume":"9","author":"EA Idelevich","year":"2014","unstructured":"Idelevich EA, Grunewald CM, W\u00fcllenweber J, Becker K (2014) Rapid identification and susceptibility testing of Candida spp. from positive blood cultures by combination of direct MALDI-TOF mass spectrometry and direct inoculation of Vitek 2. PLoS One 9:e114834. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0114834","journal-title":"PLoS One"},{"key":"5599_CR43","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1128\/JCM.00028-13","volume":"51","author":"NRH Stone","year":"2013","unstructured":"Stone NRH, Gorton RL, Barker K et al (2013) Evaluation of PNA-FISH yeast traffic light for rapid identification of yeast directly from positive blood cultures and assessment of clinical impact. J Clin Microbiol 51:1301\u20131302. \n                    https:\/\/doi.org\/10.1128\/JCM.00028-13","journal-title":"J Clin Microbiol"},{"key":"5599_CR44","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1128\/AAC.02155-13","volume":"58","author":"J Guinea","year":"2014","unstructured":"Guinea J, Zaragoza \u00d3, Escribano P et al (2014) Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother 58:1529\u20131537. \n                    https:\/\/doi.org\/10.1128\/AAC.02155-13","journal-title":"Antimicrob Agents Chemother"},{"key":"5599_CR45","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1128\/JCM.01602-10","volume":"49","author":"T Avni","year":"2011","unstructured":"Avni T, Leibovici L, Paul M (2011) PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol 49:665\u2013670. \n                    https:\/\/doi.org\/10.1128\/JCM.01602-10","journal-title":"J Clin Microbiol"},{"key":"5599_CR46","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1128\/JCM.00147-10","volume":"48","author":"F Lamoth","year":"2010","unstructured":"Lamoth F, Jaton K, Prod\u2019hom G et al (2010) Multiplex blood PCR in combination with blood cultures for improvement of microbiological documentation of infection in febrile neutropenia. J Clin Microbiol 48:3510\u20133516. \n                    https:\/\/doi.org\/10.1128\/JCM.00147-10","journal-title":"J Clin Microbiol"},{"key":"5599_CR47","doi-asserted-by":"publisher","first-page":"e0158186","DOI":"10.1371\/journal.pone.0158186","volume":"11","author":"D Metzgar","year":"2016","unstructured":"Metzgar D, Frinder MW, Rothman RE et al (2016) The IRIDICA BAC BSI Assay: rapid, sensitive and culture-independent identification of bacteria and candida in blood. PLoS One 11:e0158186. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0158186","journal-title":"PLoS One"},{"key":"5599_CR48","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13054-016-1324-3","volume":"20","author":"C Le\u00f3n","year":"2016","unstructured":"Le\u00f3n C, Ruiz-Santana S, Saavedra P et al (2016) Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions. Crit Care 20:149. \n                    https:\/\/doi.org\/10.1186\/s13054-016-1324-3","journal-title":"Crit Care"},{"key":"5599_CR49","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1128\/JCM.00496-17","volume":"55","author":"JT Ramos","year":"2017","unstructured":"Ramos JT, Villar S, Bouza E et al (2017) Performance of a quantitative PCR-based assay and beta-d-glucan detection for diagnosis of invasive candidiasis in very-low-birth-weight preterm neonatal patients (CANDINEO Study). J Clin Microbiol 55:2752\u20132764. \n                    https:\/\/doi.org\/10.1128\/JCM.00496-17","journal-title":"J Clin Microbiol"},{"key":"5599_CR50","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.diagmicrobio.2013.07.007","volume":"77","author":"ND Beyda","year":"2013","unstructured":"Beyda ND, Alam MJ, Garey KW (2013) Comparison of the T2Dx instrument with T2Candida assay and automated blood culture in the detection of Candida species using seeded blood samples. Diagn Microbiol Infect Dis 77:324\u2013326. \n                    https:\/\/doi.org\/10.1016\/j.diagmicrobio.2013.07.007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"5599_CR51","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/cid\/ciu959","volume":"60","author":"E Mylonakis","year":"2015","unstructured":"Mylonakis E, Clancy CJ, Ostrosky-Zeichner L et al (2015) T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis 60:892\u2013899. \n                    https:\/\/doi.org\/10.1093\/cid\/ciu959","journal-title":"Clin Infect Dis"},{"key":"5599_CR52","doi-asserted-by":"crossref","unstructured":"Mikulska M, Calandra T, Sanguinetti M et al (2010) The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care 14:R222. https:\/\/doi.org\/10.1186\/cc9365","DOI":"10.1186\/cc9365"},{"key":"5599_CR53","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1093\/jac\/dkv090","volume":"70","author":"MC Mart\u00ednez-Jim\u00e9nez","year":"2015","unstructured":"Mart\u00ednez-Jim\u00e9nez MC, Mu\u00f1oz P, Valerio M et al (2015) Candida biomarkers in patients with candidaemia and bacteraemia. J Antimicrob Chemother 70:2354\u20132361. \n                    https:\/\/doi.org\/10.1093\/jac\/dkv090","journal-title":"J Antimicrob Chemother"},{"key":"5599_CR54","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1164\/rccm.201211-2069OC","volume":"188","author":"F Tissot","year":"2013","unstructured":"Tissot F, Lamoth F, Hauser PM et al (2013) \u03b2-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med 188:1100\u20131109. \n                    https:\/\/doi.org\/10.1164\/rccm.201211-2069OC","journal-title":"Am J Respir Crit Care Med"},{"key":"5599_CR55","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B Pauw De","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) C. Clin Infect Dis 46:1813\u20131821. \n                    https:\/\/doi.org\/10.1086\/588660","journal-title":"Clin Infect Dis"},{"key":"5599_CR56","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1128\/JCM.02091-07","volume":"46","author":"F Persat","year":"2008","unstructured":"Persat F, Ranque S, Derouin F et al (2008) Contribution of the (1---3)-beta-d-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 46:1009\u20131013. \n                    https:\/\/doi.org\/10.1128\/JCM.02091-07","journal-title":"J Clin Microbiol"},{"key":"5599_CR57","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00134-012-2616-y","volume":"38","author":"C Le\u00f3n","year":"2012","unstructured":"Le\u00f3n C, Ruiz-Santana S, Saavedra P et al (2012) Value of \u03b2-d-glucan and Candida albicans germ tube antibody for discriminating between Candida colonization and invasive candidiasis in patients with severe abdominal conditions. Intensive Care Med 38:1315\u20131325. \n                    https:\/\/doi.org\/10.1007\/s00134-012-2616-y","journal-title":"Intensive Care Med"},{"key":"5599_CR58","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1093\/jac\/dkw112","volume":"71","author":"B Posteraro","year":"2016","unstructured":"Posteraro B, Tumbarello M, De Pascale G et al (2016) (1,3)-\u03b2-d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study. J Antimicrob Chemother 71:2262\u20132269. \n                    https:\/\/doi.org\/10.1093\/jac\/dkw112","journal-title":"J Antimicrob Chemother"},{"key":"5599_CR59","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11046-016-0011-x","volume":"181","author":"T Lahmer","year":"2016","unstructured":"Lahmer T, Rasch S, Schnappauf C et al (2016) Comparison of serum galactomannan and 1,3-beta-d-glucan determination for early detection of invasive pulmonary aspergillosis in critically ill patients with hematological malignancies and septic shock. Mycopathologia 181:505\u2013511. \n                    https:\/\/doi.org\/10.1007\/s11046-016-0011-x","journal-title":"Mycopathologia"},{"key":"5599_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-018-5175-z","author":"CM Coopersmith","year":"2018","unstructured":"Coopersmith CM, de Backer D, Deutschman CS et al (2018) Surviving sepsis campaign: research priorities for sepsis and septic shock. Intensive Care Med. \n                    https:\/\/doi.org\/10.1007\/s00134-018-5175-z","journal-title":"Intensive Care Med"},{"key":"5599_CR61","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/bja\/aew117","volume":"117","author":"M Guilbart","year":"2016","unstructured":"Guilbart M, Zogheib E, Ntouba A et al (2016) Compliance with an empirical antimicrobial protocol improves the outcome of complicated intra-abdominal infections: a prospective observational study. Br J Anaesth 117:66\u201372. \n                    https:\/\/doi.org\/10.1093\/bja\/aew117","journal-title":"Br J Anaesth"},{"key":"5599_CR62","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.clinthera.2014.06.028","volume":"36","author":"ST Micek","year":"2014","unstructured":"Micek ST, Arnold H, Juang P et al (2014) Effects of empiric antifungal therapy for septic shock on time to appropriate therapy for Candida infection: a pilot study. Clin Ther 36:1226\u20131232. \n                    https:\/\/doi.org\/10.1016\/j.clinthera.2014.06.028","journal-title":"Clin Ther"},{"key":"5599_CR63","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/jac\/dks347","volume":"68","author":"J Garnacho-Montero","year":"2013","unstructured":"Garnacho-Montero J, D\u00edaz-Mart\u00edn A, Garc\u00eda-Cabrera E et al (2013) Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections. J Antimicrob Chemother 68:206\u2013213. \n                    https:\/\/doi.org\/10.1093\/jac\/dks347","journal-title":"J Antimicrob Chemother"},{"key":"5599_CR64","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1517\/17460441.2013.807245","volume":"8","author":"CG Pierce","year":"2013","unstructured":"Pierce CG, Lopez-Ribot JL (2013) Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. Expert Opin Drug Discov 8:1117\u20131126. \n                    https:\/\/doi.org\/10.1517\/17460441.2013.807245","journal-title":"Expert Opin Drug Discov"},{"key":"5599_CR65","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/jac\/dki491","volume":"57","author":"EG Playford","year":"2006","unstructured":"Playford EG, Webster AC, Sorrell TC, Craig JC (2006) Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 57:628\u2013638. \n                    https:\/\/doi.org\/10.1093\/jac\/dki491","journal-title":"J Antimicrob Chemother"},{"key":"5599_CR66","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1097\/01.CCM.0000178352.14703.49","volume":"33","author":"AF Shorr","year":"2005","unstructured":"Shorr AF, Chung K, Jackson WL et al (2005) Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 33:1928\u20131935 (quiz 1936)","journal-title":"Crit Care Med"},{"key":"5599_CR67","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1097\/01.CCM.0000208357.05675.C3","volume":"34","author":"KZ Vardakas","year":"2006","unstructured":"Vardakas KZ, Samonis G, Michalopoulos A et al (2006) Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. Crit Care Med 34:1216\u20131224. \n                    https:\/\/doi.org\/10.1097\/01.CCM.0000208357.05675.C3","journal-title":"Crit Care Med"},{"key":"5599_CR68","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s00134-005-2794-y","volume":"31","author":"M Cruciani","year":"2005","unstructured":"Cruciani M, de Lalla F, Mengoli C (2005) Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med 31:1479\u20131487. \n                    https:\/\/doi.org\/10.1007\/s00134-005-2794-y","journal-title":"Intensive Care Med"},{"key":"5599_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd004920.pub2","author":"EG Playford","year":"2006","unstructured":"Playford EG, Webster AC, Sorrell TC, Craig JC (2006) Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev. \n                    https:\/\/doi.org\/10.1002\/14651858.cd004920.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"5599_CR70","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.3389\/fmicb.2016.02173","volume":"7","author":"SG Whaley","year":"2016","unstructured":"Whaley SG, Berkow EL, Rybak JM et al (2016) Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Front Microbiol 7:2173. \n                    https:\/\/doi.org\/10.3389\/fmicb.2016.02173","journal-title":"Front Microbiol"},{"key":"5599_CR71","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1086\/596757","volume":"48","author":"PG Pappas","year":"2009","unstructured":"Pappas PG, Kauffman CA, Andes D et al (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503\u2013535. \n                    https:\/\/doi.org\/10.1086\/596757","journal-title":"Clin Infect Dis"},{"key":"5599_CR72","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1155\/2010\/357076","volume":"21","author":"EJ Bow","year":"2010","unstructured":"Bow EJ, Evans G, Fuller J et al (2010) Canadian clinical practice guidelines for invasive candidiasis in adults. Can J Infect Dis Med Microbiol 21:e122\u2013e150","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"5599_CR73","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10096-016-2796-4","volume":"36","author":"Y-K Pang","year":"2017","unstructured":"Pang Y-K, Ip M, You JHS (2017) Potential clinical and economic outcomes of active beta-d-glucan surveillance with preemptive therapy for invasive candidiasis at intensive care units: a decision model analysis. Eur J Clin Microbiol Infect Dis 36:187\u2013194. \n                    https:\/\/doi.org\/10.1007\/s10096-016-2796-4","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5599_CR74","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/CCM.0b013e318236f297","volume":"40","author":"E Azoulay","year":"2012","unstructured":"Azoulay E, Dupont HH, Tabah A et al (2012) Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Crit Care Med 40:813\u2013822. \n                    https:\/\/doi.org\/10.1097\/CCM.0b013e318236f297","journal-title":"Crit Care Med"},{"key":"5599_CR75","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/IDR.S38945","volume":"6","author":"H Wissing","year":"2013","unstructured":"Wissing H, Ballus J, Bingold TM et al (2013) Intensive care unit-related fluconazole use in Spain and Germany: patient characteristics and outcomes of a prospective multicenter longitudinal observational study. Infect Drug Resist 6:15\u201325. \n                    https:\/\/doi.org\/10.2147\/IDR.S38945","journal-title":"Infect Drug Resist"},{"key":"5599_CR76","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1097\/01.CCM.0000147726.62304.7F","volume":"32","author":"R Piarroux","year":"2004","unstructured":"Piarroux R, Grenouillet F, Balvay P et al (2004) Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 32:2443\u20132449","journal-title":"Crit Care Med"},{"key":"5599_CR77","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1164\/rccm.201409-1701OC","volume":"191","author":"S Bailly","year":"2015","unstructured":"Bailly S, Bouadma L, Azoulay E et al (2015) Failure of empirical systemic antifungal therapy in mechanically ventilated critically ill patients. Am J Respir Crit Care Med 191:1139\u20131146. \n                    https:\/\/doi.org\/10.1164\/rccm.201409-1701OC","journal-title":"Am J Respir Crit Care Med"},{"key":"5599_CR78","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13613-015-0103-7","volume":"6","author":"O Leroy","year":"2016","unstructured":"Leroy O, Bailly S, Gangneux J-P et al (2016) Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study. Ann Intensive Care 6:2. \n                    https:\/\/doi.org\/10.1186\/s13613-015-0103-7","journal-title":"Ann Intensive Care"},{"key":"5599_CR79","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-143-12-200512200-00004","volume":"143","author":"Y Golan","year":"2005","unstructured":"Golan Y, Wolf MP, Pauker SG et al (2005) Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Ann Intern Med 143:857\u2013869","journal-title":"Ann Intern Med"},{"key":"5599_CR80","doi-asserted-by":"publisher","first-page":"83","DOI":"10.7326\/0003-4819-149-2-200807150-00004","volume":"149","author":"MG Schuster","year":"2008","unstructured":"Schuster MG, Edwards JE, Sobel JD et al (2008) Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 149:83\u201390","journal-title":"Ann Intern Med"},{"key":"5599_CR81","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.14655","author":"J-F Timsit","year":"2016","unstructured":"Timsit J-F, Azoulay E, Schwebel C et al (2016) Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure: the EMPIRICUS randomized clinical trial. JAMA. \n                    https:\/\/doi.org\/10.1001\/jama.2016.14655","journal-title":"JAMA"},{"key":"5599_CR82","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1128\/AAC.02461-15","volume":"60","author":"MG Sinnollareddy","year":"2016","unstructured":"Sinnollareddy MG, Roberts MS, Lipman J et al (2016) In vivo microdialysis to determine subcutaneous interstitial fluid penetration and pharmacokinetics of fluconazole in intensive care unit patients with sepsis. Antimicrob Agents Chemother 60:827\u2013832. \n                    https:\/\/doi.org\/10.1128\/AAC.02461-15","journal-title":"Antimicrob Agents Chemother"},{"key":"5599_CR83","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13054-015-0758-3","volume":"19","author":"MG Sinnollareddy","year":"2015","unstructured":"Sinnollareddy MG, Roberts JA, Lipman J et al (2015) Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. Crit Care 19:33. \n                    https:\/\/doi.org\/10.1186\/s13054-015-0758-3","journal-title":"Crit Care"},{"issue":"Suppl 6","key":"5599_CR84","doi-asserted-by":"publisher","first-page":"S612","DOI":"10.1093\/cid\/civ791","volume":"61","author":"DS Perlin","year":"2015","unstructured":"Perlin DS (2015) Echinocandin resistance in Candida. Clin Infect Dis 61(Suppl 6):S612\u2013S617. \n                    https:\/\/doi.org\/10.1093\/cid\/civ791","journal-title":"Clin Infect Dis"},{"key":"5599_CR85","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1128\/JCM.00566-08","volume":"46","author":"MA Pfaller","year":"2008","unstructured":"Pfaller MA, Diekema DJ, Ostrosky-Zeichner L et al (2008) Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 46:2620\u20132629. \n                    https:\/\/doi.org\/10.1128\/JCM.00566-08","journal-title":"J Clin Microbiol"},{"key":"5599_CR86","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1097\/CCM.0000000000000221","volume":"42","author":"M Puig-Asensio","year":"2014","unstructured":"Puig-Asensio M, Pem\u00e1n J, Zaragoza R et al (2014) Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Crit Care Med 42:1423\u20131432. \n                    https:\/\/doi.org\/10.1097\/CCM.0000000000000221","journal-title":"Crit Care Med"},{"key":"5599_CR87","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1093\/jac\/dku313","volume":"69","author":"EW Muilwijk","year":"2014","unstructured":"Muilwijk EW, Schouten JA, van Leeuwen HJ et al (2014) Pharmacokinetics of caspofungin in ICU patients. J Antimicrob Chemother 69:3294\u20133299. \n                    https:\/\/doi.org\/10.1093\/jac\/dku313","journal-title":"J Antimicrob Chemother"},{"key":"5599_CR88","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1128\/AAC.00623-15","volume":"59","author":"VJ Lempers","year":"2015","unstructured":"Lempers VJ, Schouten JA, Hunfeld NG et al (2015) Altered micafungin pharmacokinetics in intensive care unit patients. Antimicrob Agents Chemother 59:4403\u20134409. \n                    https:\/\/doi.org\/10.1128\/AAC.00623-15","journal-title":"Antimicrob Agents Chemother"},{"key":"5599_CR89","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1093\/jac\/dkv173","volume":"70","author":"S Grau","year":"2015","unstructured":"Grau S, Luque S, Campillo N et al (2015) Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. J Antimicrob Chemother 70:2854\u20132861. \n                    https:\/\/doi.org\/10.1093\/jac\/dkv173","journal-title":"J Antimicrob Chemother"},{"key":"5599_CR90","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/jac\/dkw568","volume":"72","author":"H Dupont","year":"2017","unstructured":"Dupont H, Massias L, Jung B et al (2017) Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis. J Antimicrob Chemother 72:1429\u20131432. \n                    https:\/\/doi.org\/10.1093\/jac\/dkw568","journal-title":"J Antimicrob Chemother"},{"key":"5599_CR91","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1086\/504492","volume":"43","author":"ESD Ashley","year":"2006","unstructured":"Ashley ESD, Lewis R, Lewis JS et al (2006) Pharmacology of systemic antifungal agents. Clin Infect Dis 43:S28\u2013S39. \n                    https:\/\/doi.org\/10.1086\/504492","journal-title":"Clin Infect Dis"},{"key":"5599_CR92","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa021585","volume":"347","author":"J Mora-Duarte","year":"2002","unstructured":"Mora-Duarte J, Betts R, Rotstein C et al (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020\u20132029. \n                    https:\/\/doi.org\/10.1056\/NEJMoa021585","journal-title":"N Engl J Med"},{"key":"5599_CR93","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","volume":"369","author":"E-R Kuse","year":"2007","unstructured":"Kuse E-R, Chetchotisakd P, da Cunha CA et al (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369:1519\u20131527. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(07)60605-9","journal-title":"Lancet"},{"key":"5599_CR94","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s15010-013-0558-0","volume":"42","author":"L Scudeller","year":"2014","unstructured":"Scudeller L, Viscoli C, Menichetti F et al (2014) An Italian consensus for invasive candidiasis management (ITALIC). Infection 42:263\u2013279. \n                    https:\/\/doi.org\/10.1007\/s15010-013-0558-0","journal-title":"Infection"},{"key":"5599_CR95","doi-asserted-by":"publisher","first-page":"R253","DOI":"10.1186\/cc10514","volume":"15","author":"DH Kett","year":"2011","unstructured":"Kett DH, Shorr AF, Reboli AC et al (2011) Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. Crit Care 15:R253. \n                    https:\/\/doi.org\/10.1186\/cc10514","journal-title":"Crit Care"},{"key":"5599_CR96","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/cc10580","volume":"15","author":"J Gon\u00e7alves-Pereira","year":"2011","unstructured":"Gon\u00e7alves-Pereira J, P\u00f3voa P (2011) Echinocandins\u2014first line in invasive candidiasis: how strong is this \u201cstrong\u201d evidence? Crit Care 15:461. \n                    https:\/\/doi.org\/10.1186\/cc10580\n                    \n                  \n                           (author reply 461)","journal-title":"Crit Care"},{"key":"5599_CR97","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1093\/cid\/cis021","volume":"54","author":"DR Andes","year":"2012","unstructured":"Andes DR, Safdar N, Baddley JW et al (2012) Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 54:1110\u20131122. \n                    https:\/\/doi.org\/10.1093\/cid\/cis021","journal-title":"Clin Infect Dis"},{"key":"5599_CR98","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10096-015-2527-2","volume":"35","author":"R Murri","year":"2016","unstructured":"Murri R, Scoppettuolo G, Ventura G et al (2016) Initial antifungal strategy does not correlate with mortality in patients with candidemia. Eur J Clin Microbiol Infect Dis 35:187\u2013193. \n                    https:\/\/doi.org\/10.1007\/s10096-015-2527-2","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5599_CR99","first-page":"345","volume":"125","author":"Q Chen","year":"2012","unstructured":"Chen Q, Lin M-H, Chen M-L et al (2012) Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials. Chin Med J (Engl) 125:345\u2013351","journal-title":"Chin Med J (Engl)"},{"key":"5599_CR100","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s10096-014-2287-4","volume":"34","author":"J-F Wang","year":"2015","unstructured":"Wang J-F, Xue Y, Zhu X-B, Fan H (2015) Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs. Eur J Clin Microbiol Infect Dis 34:651\u2013659. \n                    https:\/\/doi.org\/10.1007\/s10096-014-2287-4","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5599_CR101","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/CCM.0000000000002867","volume":"46","author":"J Garnacho-Montero","year":"2018","unstructured":"Garnacho-Montero J, D\u00edaz-Mart\u00edn A, Cant\u00f3n-Bulnes L et al (2018) Initial antifungal strategy reduces mortality in critically ill patients with candidemia: a propensity score-adjusted analysis of a multicenter study. Crit Care Med 46:384\u2013393. \n                    https:\/\/doi.org\/10.1097\/CCM.0000000000002867","journal-title":"Crit Care Med"},{"key":"5599_CR102","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/pds.1365","volume":"16","author":"KW Garey","year":"2007","unstructured":"Garey KW, Pai MP, Suda KJ et al (2007) Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf 16:919\u2013927. \n                    https:\/\/doi.org\/10.1002\/pds.1365","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5599_CR103","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.ijantimicag.2016.02.004","volume":"47","author":"Q Yang","year":"2016","unstructured":"Yang Q, Wang T, Xie J et al (2016) Pharmacokinetic\/pharmacodynamic adequacy of echinocandins against Candida spp. in intensive care unit patients and general patient populations. Int J Antimicrob Agents 47:397\u2013402. \n                    https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.02.004","journal-title":"Int J Antimicrob Agents"},{"key":"5599_CR104","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1093\/jac\/dky189","volume":"73","author":"T Gustot","year":"2018","unstructured":"Gustot T, Ter Heine R, Brauns E et al (2018) Caspofungin dosage adjustments are not required for patients with Child-Pugh B or C cirrhosis. J Antimicrob Chemother 73:2493\u20132496. \n                    https:\/\/doi.org\/10.1093\/jac\/dky189","journal-title":"J Antimicrob Chemother"},{"key":"5599_CR105","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1128\/AAC.48.11.4453-4456.2004","volume":"48","author":"G Bonaventura Di","year":"2004","unstructured":"Di Bonaventura G, Spedicato I, Picciani C et al (2004) In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies. Antimicrob Agents Chemother 48:4453\u20134456. \n                    https:\/\/doi.org\/10.1128\/AAC.48.11.4453-4456.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"5599_CR106","doi-asserted-by":"publisher","first-page":"805","DOI":"10.4065\/mcp.2011.0247","volume":"86","author":"RE Lewis","year":"2011","unstructured":"Lewis RE (2011) Current concepts in antifungal pharmacology. Mayo Clin Proc 86:805\u2013817. \n                    https:\/\/doi.org\/10.4065\/mcp.2011.0247","journal-title":"Mayo Clin Proc"},{"key":"5599_CR107","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd000969","author":"HK Johansen","year":"2000","unstructured":"Johansen HK, Gotzsche PC (2000) Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev. \n                    https:\/\/doi.org\/10.1002\/14651858.cd000969","journal-title":"Cochrane Database Syst Rev"},{"key":"5599_CR108","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1528872","author":"S Keane","year":"2018","unstructured":"Keane S, Geoghegan P, Povoa P et al (2018) Systematic review on the first line treatment of amphotericin B in critically ill adults with candidemia or invasive candidiasis. Expert Rev Anti Infect Ther. \n                    https:\/\/doi.org\/10.1080\/14787210.2018.1528872","journal-title":"Expert Rev Anti Infect Ther"},{"key":"5599_CR109","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/jof3010008","volume":"3","author":"S Silva","year":"2017","unstructured":"Silva S, Rodrigues C, Ara\u00fajo D et al (2017) Candida species biofilms\u2019 antifungal resistance. J Fungi 3:8. \n                    https:\/\/doi.org\/10.3390\/jof3010008","journal-title":"J Fungi"},{"key":"5599_CR110","first-page":"95","volume-title":"Updates on therapeutic strategies against Candida (and Aspergillus) biofilm related infections","author":"FK Muakkassa","year":"2016","unstructured":"Muakkassa FK, Ghannoum M (2016) Updates on therapeutic strategies against Candida (and Aspergillus) biofilm related infections. Springer, Cham, pp 95\u2013103"},{"key":"5599_CR111","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.medin.2017.09.012","volume":"42","author":"F Chaves","year":"2018","unstructured":"Chaves F, Garnacho-Montero J, Del Pozo JL et al (2018) Diagnosis and treatment of catheter-related bloodstream infection: clinical guidelines of the Spanish society of infectious diseases and clinical microbiology and (SEIMC) and the Spanish society of Spanish society of intensive and critical care medicine A. Med Intens 42:5\u201336. \n                    https:\/\/doi.org\/10.1016\/j.medin.2017.09.012","journal-title":"Med Intens"},{"key":"5599_CR112","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1471-2334-14-97","volume":"14","author":"J Vazquez","year":"2014","unstructured":"Vazquez J, Reboli AC, Pappas PG et al (2014) Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial. BMC Infect Dis 14:97. \n                    https:\/\/doi.org\/10.1186\/1471-2334-14-97","journal-title":"BMC Infect Dis"},{"key":"5599_CR113","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s00134-015-4053-1","volume":"41","author":"S Bailly","year":"2015","unstructured":"Bailly S, Leroy O, Montravers P et al (2015) Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data. Intensive Care Med 41:1931\u20131940. \n                    https:\/\/doi.org\/10.1007\/s00134-015-4053-1","journal-title":"Intensive Care Med"},{"key":"5599_CR114","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11096-012-9712-5","volume":"35","author":"AJ Guarascio","year":"2013","unstructured":"Guarascio AJ, Slain D, McKnight R et al (2013) A matched-control evaluation of an antifungal bundle in the intensive care unit at a university teaching hospital. Int J Clin Pharm 35:145\u2013148. \n                    https:\/\/doi.org\/10.1007\/s11096-012-9712-5","journal-title":"Int J Clin Pharm"},{"key":"5599_CR115","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1093\/jac\/dkv241","volume":"70","author":"MC Mart\u00ednez-Jim\u00e9nez","year":"2015","unstructured":"Mart\u00ednez-Jim\u00e9nez MC, Mu\u00f1oz P, Valerio M et al (2015) Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment. J Antimicrob Chemother 70:3107\u20133115. \n                    https:\/\/doi.org\/10.1093\/jac\/dkv241","journal-title":"J Antimicrob Chemother"},{"key":"5599_CR116","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1007\/s00134-017-4932-8","volume":"43","author":"A Rouz\u00e9","year":"2017","unstructured":"Rouz\u00e9 A, Loridant S, Poissy J et al (2017) Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial. Intensive Care Med 43:1668\u20131677. \n                    https:\/\/doi.org\/10.1007\/s00134-017-4932-8","journal-title":"Intensive Care Med"},{"key":"5599_CR117","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00134-015-3866-2","volume":"41","author":"M Bassetti","year":"2015","unstructured":"Bassetti M, Righi E, Ansaldi F et al (2015) A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med 41:1601\u20131610. \n                    https:\/\/doi.org\/10.1007\/s00134-015-3866-2","journal-title":"Intensive Care Med"},{"key":"5599_CR118","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1055\/s-0035-1562891","volume":"36","author":"CA Kauffman","year":"2015","unstructured":"Kauffman CA (2015) Complications of candidemia in ICU patients: endophthalmitis, osteomyelitis, endocarditis. Semin Respir Crit Care Med 36:641\u2013649. \n                    https:\/\/doi.org\/10.1055\/s-0035-1562891","journal-title":"Semin Respir Crit Care Med"},{"key":"5599_CR119","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s10096-015-2384-z","volume":"34","author":"A Fern\u00e1ndez-Cruz","year":"2015","unstructured":"Fern\u00e1ndez-Cruz A, Cruz Men\u00e1rguez M, Mu\u00f1oz P et al (2015) The search for endocarditis in patients with candidemia: a systematic recommendation for echocardiography? A prospective cohort. Eur J Clin Microbiol Infect Dis 34:1543\u20131549. \n                    https:\/\/doi.org\/10.1007\/s10096-015-2384-z","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5599_CR120","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/01.md.0000076008.64510.f1","volume":"82","author":"LJ Rodr\u00edguez-Adri\u00e1n","year":"2003","unstructured":"Rodr\u00edguez-Adri\u00e1n LJ, King RT, Tamayo-Derat LG et al (2003) Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology. Med (Baltim) 82:187\u2013202. \n                    https:\/\/doi.org\/10.1097\/01.md.0000076008.64510.f1","journal-title":"Med (Baltim)"},{"key":"5599_CR121","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1086\/375603","volume":"37","author":"JJ Waele De","year":"2003","unstructured":"De Waele JJ, Vogelaers D, Blot S, Colardyn F (2003) Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. Clin Infect Dis 37:208\u2013213. \n                    https:\/\/doi.org\/10.1086\/375603","journal-title":"Clin Infect Dis"},{"key":"5599_CR122","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1345\/aph.1K010","volume":"41","author":"R Tsuruta","year":"2007","unstructured":"Tsuruta R, Mizuno H, Kaneko T et al (2007) Preemptive therapy in nonneutropenic patients with Candida infection using the Japanese guidelines. Ann Pharmacother 41:1137\u20131143. \n                    https:\/\/doi.org\/10.1345\/aph.1K010","journal-title":"Ann Pharmacother"},{"key":"5599_CR123","doi-asserted-by":"publisher","first-page":"e42282","DOI":"10.1371\/journal.pone.0042282","volume":"7","author":"KE Hanson","year":"2012","unstructured":"Hanson KE, Pfeiffer CD, Lease ED et al (2012) \u03b2-d-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS One 7:e42282. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0042282","journal-title":"PLoS One"},{"key":"5599_CR124","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/cid\/ciu074","volume":"58","author":"L Ostrosky-Zeichner","year":"2014","unstructured":"Ostrosky-Zeichner L, Shoham S, Vazquez J et al (2014) MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis 58:1219\u20131226. \n                    https:\/\/doi.org\/10.1093\/cid\/ciu074","journal-title":"Clin Infect Dis"},{"key":"5599_CR125","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/myc.12221","volume":"57","author":"J Prattes","year":"2014","unstructured":"Prattes J, Hoenigl M, Rabensteiner J et al (2014) Serum 1,3-beta-d-glucan for antifungal treatment stratification at the intensive care unit and the influence of surgery. Mycoses 57:679\u2013686. \n                    https:\/\/doi.org\/10.1111\/myc.12221","journal-title":"Mycoses"},{"key":"5599_CR126","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/cid\/civ707","volume":"61","author":"W Knitsch","year":"2015","unstructured":"Knitsch W, Vincent J-L, Utzolino S et al (2015) A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections. Clin Infect Dis 61:1671\u20131678. \n                    https:\/\/doi.org\/10.1093\/cid\/civ707","journal-title":"Clin Infect Dis"},{"key":"5599_CR127","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/cid\/cis305","volume":"54","author":"M Kollef","year":"2012","unstructured":"Kollef M, Micek S, Hampton N et al (2012) Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 54:1739\u20131746. \n                    https:\/\/doi.org\/10.1093\/cid\/cis305","journal-title":"Clin Infect Dis"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-019-05599-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00134-019-05599-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-019-05599-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:04:20Z","timestamp":1585008260000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00134-019-05599-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,25]]},"references-count":127,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["5599"],"URL":"https:\/\/doi.org\/10.1007\/s00134-019-05599-w","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,25]]},"assertion":[{"value":"6 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"COIs declared by the authors: IML: Lectures: Thermofisher, Polyphor, J&J, Virogates, MSD. Advisory board: Fresenius Kabi, MaaT Pharma, Bayer, Gilead, Clinigen, Biotest, Accelerate. JGM has received speaker honoraria from Astellas and MSD. MB has participated in the past five years in advisory boards and\/or received speaker honoraria from Achaogen, Angelini, Astellas, AstraZeneca, Bayer, Basilea, Cidara, Gilead, Menarini, MSD, Nabriva, Paratek, Pfizer, Roche, The Medicine Company, Shionogi, Tetraphase, VenatoRx, and Vifor. SSK has received honoraria for participating in advisory boards or as a speaker for Merck, Pfizer, Hikma, Pasteur Aventis, Gilead. JDW has consulted for Accelerate, AtoxBio, Bayer Healthcare, Cubist, MSD, Pfizer (honoraria were paid to his institution). PM: Personal fees and non-financial support from Astellas, Astrazeneca, Basilea, Bayer, Cubist, Menarini, MSD, Parexel, Pfizer, Tetraphase, and The Medicines Company unrelated to the submitted work. GD: Advisory boards and\/or received speaker honoraria from Astellas, Bayer, Cidara, Gilead, MSD, Nabriva, Paratek, Pfizer, Tetraphase, Cipla India, Glenmark India, Infectopharm Germany. MCE has received grant support from Astellas Pharma, bioMerieux, Gilead Sciences, Merck Sharp & Dohme, Pfizer, Schering Plough, CIDARA, Amplyx, F2G, Scynexis, Soria Melguizo SA, and Ferrer International. He is a founding Partner of the start-up Micolog\u00eda Molecular SL.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"An approval by an ethics committee was not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}